Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rugen Therapeutics
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Rugen Therapeutics developed first-in-class orally active small molecules for CNS disorders. The company demonstrated efficacy for its compounds in animal models of ASD and OCD.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Allergan (now AbbVie)McQuade Center for Strategic Research and Development (MSRD)
Beyond the preview
Go deeper on Rugen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rugen Therapeutics.